Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
abbvie
7
×
astrazeneca
7
×
biotech
7
×
boston blog main
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
7
×
indiana top stories
life sciences
national
national blog main
7
×
national top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
boston top stories
cancer
pfizer
bristol-myers squibb
clinical trials
eli lilly
fda
novartis
startups
amgen
biogen
cancer immunotherapy
What
bio
roundup
drug
acquisitions
biotech
ceo
conference
daniel
fda
gilead
news
opioid
o’day
prices
sciences
seven
week
abbvie’s
alzheimer’s
announced
annual
approved
assessed
attention
august
away
barbecuing
biggest
bringing
build
busy
buy
camping
cardiologist
center
ceos
check
cholesterol
collabs
communities
Language
unset
Current search:
astrazeneca
×
abbvie
×
" indiana blog main "
×
biotech
×
" national blog main "
×
@xconomy.com
3 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
Bio Roundup: Cholesterol Check, J&J’s Opioid Hit, AbbVie’s Flop & More
@xconomy.com
4 years ago
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More
@xconomy.com
5 years ago
Pharma CEOs to Senate: We Will Lower Drug Prices if Rebates Go Away
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Puzzle, ESMO Assessed, Drug Prices & More